Cancer Therapy News and Research

RSS

Immune cell neighborhoods control cancer spread and metastasis formation

Published in Nature Cancer: Researchers at the Université libre de Bruxelles (ULB) have discovered that immune cells build distinct "neighborhoods" around cancer cells.

3 Nov 2026

Platelet hyperactivity drives glioblastoma progression and deep vein thrombosis

New Cleveland Clinic research published in Cancer Cell shows that people with glioblastoma have more active platelets, which are cells involved in blood clotting. Platelets also communicate with other cells and can influence immune activity. The overactive platelets in people with glioblastoma slow the activity of cancer-fighting T cells, which can contribute to tumor growth and cancer progression.

30 Oct 2026

Childhood leukemia treatment causes rapid, lasting challenges for patient families

New research in the October 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network finds that families of children receiving treatment for B-cell acute lymphoblastic leukemia (B-ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a new multicenter study embedded in a Children's Oncology Group (COG) trial.

13 Oct 2026

Long non-coding RNAs offer new pathways to overcome cancer treatment resistance

Scientists are highlighting long non-coding RNAs (lncRNAs) as promising targets in the effort to overcome one of cancer treatment's most persistent challenges: therapeutic resistance.

12 Oct 2026

Adding a chatbot to specialist care helped young people make sense of cancer risk

In a randomized trial of 106 adolescents and young adults with hereditary cancer predisposition, adding AYA-RISE to a clinic visit improved knowledge of cancer risk before age 30 compared with a clinic visit alone. Researchers observed no increase in distress, but the main analyses did not establish additional benefits for lifetime-risk or screening knowledge.

12 Oct 2026

Oncopeptides confirms blood-brain-barrier penetration based on data from first patients in glioblastoma Window-of-Opportunity (WoO) study

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, today announces data from the first patients in its ongoing clinical Window-of-Opportunity (WoO) study, OP-701 (INSULA), evaluating its proprietary Peptide Drug Conjugate (PDC) platform in glioblastoma.

9 Oct 2026

$13.1 million grant backs bacterial therapies for resistant breast cancer

A scientist at Weill Cornell Medicine is working with colleagues at the University of Massachusetts Amherst on new, complementary research efforts engineering therapeutic Salmonella to target critical gaps in treatment for drug-resistant triple-negative breast cancers.

9 Oct 2026

A New Approach to Preventing Bladder Cancer Recurrence

Innovative techniques using electrical energy to treat bladder cancer may lower recurrence rates and minimize the need for radical surgical interventions.

8 Oct 2026

New mathematical model tracks how tumor environment impacts cancer therapies

Researchers from Mass General Brigham and the University of Cyprus have developed a sophisticated mathematical model to better understand how the tumor microenvironment affects the delivery and effectiveness of a new type of cancer therapy called an immunomodulatory antibody-drug conjugate (IM-ADC).

30 Sep 2026

Protein modification network plays vital role in cancer development

A review published in Genes & Diseases highlights the complex interplay between protein arginine methylation and ubiquitination, two forms of protein modification that can profoundly influence cancer development, progression and treatment response.

24 Sep 2026

New digital system helps young cancer survivors manage late treatment effects

For a young person, completing cancer treatment can mark a long-awaited return to everyday life - education, work, relationships and plans for a family.

21 Sep 2026

NUS scientists harness magnetic pulses to reprogram immune cells to fight breast cancer

Researchers from the National University of Singapore (NUS) have demonstrated an innovative approach for targeted breast cancer therapy using pulsed electromagnetic fields (PEMFs).

18 Sep 2026

Existing anti-seizure drug slows the growth of diffuse midline gliomas

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown.

17 Sep 2026

Study uncovers how interferon-alpha treats rare blood cancers

The biologic drug interferon-alpha can benefit patients with blood cancers called myeloproliferative neoplasms by forcing mutant blood stem cells to become shorter-lived white blood cells, according to a study by Weill Cornell Medicine investigators.

15 Sep 2026

Study shows how the microbiome shapes lung cancer immunotherapy outcomes

Despite the revolutionary impact of immune checkpoint inhibitors on cancer therapy, 60% to 80% of patients with NSCLC still show suboptimal responses.

9 Sep 2026

Study shows how cancer can act as a systemic disease

In their quest to understand how cancers take root, grow and spread, scientists have for the past half-century explored the genetic aberrations and microenvironmental peculiarities of tumors and their constituent cells.

28 Aug 2026

Early rasburicase treatment linked to better outcomes in tumor lysis syndrome

Tumor lysis syndrome (TLS) is a life-threatening emergency that occurs when large numbers of cancer cells break down rapidly, releasing substances such as uric acid into the bloodstream that can damage the kidneys and cause serious complications.

27 Aug 2026

UofL receives new federal funding to advance metabolic health research

Chronic health conditions such as diabetes, obesity, heart disease and metabolic liver disease have sharply increased in recent decades and are among the most urgent health challenges facing our society.

27 Aug 2026

New grants support biotechnology and cancer research projects at KIT

In its CZS Nexus program, the Carl Zeiss Foundation has awarded grants to two young scientists from the Karlsruhe Institute of Technology (KIT). The researchers will each receive EUR 1.5 million to establish their own interdisciplinary working groups at KIT.

26 Aug 2026